Depressive-like behaviors alterations induced by intranigral MPTP, 6-OHDA, LPS and rotenone models of Parkinson's disease are predominantly associated with serotonin and dopamine

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 34, Issue 6, 2010, Pages 1104-1114

  Santiago, Ronise M ^a   Barbieiro, Janaína ^a   Lima, Marcelo M S ^a   Dombrowski, Patrícia A ^a   Andreatini, Roberto ^a   Vital, Maria A B F ^a  

^a FEDERAL UNIVERSITY OF PARANÁ   (Brazil)

Author keywords

6 OHDA; Depression; MPTP; Parkinson's disease; Rotenone

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; 3,4 DIHYDROXYPHENYLACETIC ACID; DOPAMINE; HOMOVANILLIC ACID; LIPOPOLYSACCHARIDE; NORADRENALIN; OXIDOPAMINE; ROTENONE; SEROTONIN; SUCROSE;

ANHEDONIA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CORPUS STRIATUM; DEPRESSION; EMOTION; FORCED SWIMMING TEST; HIPPOCAMPUS; HISTOPATHOLOGY; HOPELESSNESS; IMMOBILIZATION; LOCOMOTION; MALE; NEUROTOXICITY; NEUROTRANSMISSION; NONHUMAN; OPEN FIELD TEST; RAT; REARING; STEREOTAXIC SURGERY; ANALYSIS OF VARIANCE; ANIMAL; ANIMAL BEHAVIOR; CHEMICALLY INDUCED; DISEASE MODEL; DRUG EFFECTS; METABOLISM; MOTOR ACTIVITY; PARKINSON DISEASE; RANDOMIZATION; WISTAR RAT;

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; ANALYSIS OF VARIANCE; ANIMALS; BEHAVIOR, ANIMAL; DEPRESSION; DISEASE MODELS, ANIMAL; DOPAMINE; HIPPOCAMPUS; LIPOPOLYSACCHARIDES; MALE; MOTOR ACTIVITY; OXIDOPAMINE; PARKINSON DISEASE, SECONDARY; RANDOM ALLOCATION; RATS; RATS, WISTAR; ROTENONE; SEROTONIN;

EID: 77955057715     PISSN: 02785846     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2010.06.004     Document Type: Article

References (52)

1. Bjorklund A., Rosenblad C., Winkler C., Kirik D. Studies on neuroprotective and regenerative effects of GDNF in a partial lesion model of Parkinson's disease. Neurobiol Dis 1997, 4:186-200.
2. Blandini F., Nappi G., Tassorelli C., Martignoni E. Functional changes of the basal ganglia circuitry in Parkinson's disease. Prog Neurobiol 2000, 62:63-88.
3. Castano A., Herrera A.J., Cano J., Machado A. The degenerative effect of a single intranigral injection of LPS on the dopaminergic system is prevented by dexamethasone, and not mimicked by rh-TNF-alpha, IL-1beta and IFN-gamma. J Neurochem 2002, 81:150-157.
4. Ceravolo R., Sgado P., Frosini D., Corsini G.U. Assessing neuroprotection in Parkinson's disease: from the animal models to molecular neuroimaging in vivo. J Neural Transm Suppl 2006, 133-141.
5. Chen P., Kales H.C., Weintraub D., Blow F.C., Jiang L., Mellow A.M. Antidepressant treatment of veterans with Parkinson's disease and depression: analysis of a national sample. J Geriatr Psychiatry Neurol 2007, 20:161-165.
6. Da Cunha C., Gevaerd M.S., Vital M.A., Miyoshi E., Andreatini R., Silveira R., et al. Memory disruption in rats with nigral lesions induced by MPTP: a model for early Parkinson's disease amnesia. Behav Brain Res 2001, 124:9-18.
7. Da Cunha C., Silva M.H., Wietzikoski S., Wietzikoski E.C., Ferro M.M., Kouzmine I., et al. Place learning strategy of substantia nigra pars compacta-lesioned rats. Behav Neurosci 2006, 120:1279-1284.
8. Detke M.J., Rickels M., Lucki I. Active behaviors in the rat forced swimming test differentially produced by serotonergic and noradrenergic antidepressants. Psychopharmacology (Berl) 1995, 121:66-72.
9. Dremencov E., Newman M.E., Kinor N., Blatman-Jan G., Schindler C.J., Overstreet D.H., et al. Hyperfunctionality of serotonin-2C receptor-mediated inhibition of accumbal dopamine release in an animal model of depression is reversed by antidepressant treatment. Neuropharmacology 2005, 48:34-42.
10. Dutta G., Zhang P., Liu B. The lipopolysaccharide Parkinson's disease animal model: mechanistic studies and drug discovery. Fundam Clin Pharmacol 2008, 22:453-464.
11. Enz A., Hefti F., Frick W. Acute administration of 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine (MPTP) reduces dopamine and serotonin but accelerates norepinephrine metabolism in the rat brain. Effect of chronic pretreatment with MPTP. Eur J Pharmacol 1984, 101:37-44.
12. Ferro M.M., Bellissimo M.I., Anselmo-Franci J.A., Angellucci M.E., Canteras N.S., Da Cunha C. Comparison of bilaterally 6-OHDA- and MPTP-lesioned rats as models of the early phase of Parkinson's disease: histological, neurochemical, motor and memory alterations. J Neurosci Meth 2005, 148:78-87.
13. Frisina P.G., Haroutunian V., Libow L.S. The neuropathological basis for depression in Parkinson's disease. Parkinsonism Relat Disord 2009, 15:144-148.
14. Kobayashi T., Hayashi E., Shimamura M., Kinoshita M., Murphy N.P. Neurochemical responses to antidepressants in the prefrontal cortex of mice and their efficacy in preclinical models of anxiety-like and depression-like behavior: a comparative and correlational study. Psychopharmacology (Berl) 2008, 197:567-580.
15. Kryzhanovskii G.N., Krupina N.A., Kucherianu V.G. A new model of an experimental depressive syndrome in rats induced by the systemic administration to the animals of 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine. Zh Vyssh Nerv Deiat Im IP Pavlova 1995, 45:377-387.
16. Lapointe N., St-Hilaire M., Martinoli M.G., Blanchet J., Gould P., Rouillard C., et al. Rotenone induces non-specific central nervous system and systemic toxicity. FASEB J 2004, 18:717-719.
17. Leentjens A.F., Van den Akker M., Metsemakers J.F., Lousberg R., Verhey F.R. Higher incidence of depression preceding the onset of Parkinson's disease: a register study. Mov Disord 2003, 18:414-418.
18. Lieberman A. Depression in Parkinson's disease-a review. Acta Neurol Scand 2006, 113:1-8.
19. Lima M.M.S., Braga Reksidler A., Marques Zanata S., Bueno Machado H., Tufik S., Vital M.A. Different parkinsonism models produce a time-dependent induction of COX-2 in the substantia nigra of rats. Brain Res 2006, 1101:117-125.
20. Lima M.M.S., Andersen M.L., Reksidler A.B., Vital M.A.B.F., Tufik S. The role of the substantia nigra pars compacta in regulating sleep patterns in rats. PLoS ONE 2007, 2:e513.
21. Ling Z., Zhu Y., Tong C., Snyder J.A., Lipton J.W., Carvey P.M. Progressive dopamine neuron loss following supra-nigral lipopolysaccharide (LPS) infusion into rats exposed to LPS prenatally. Exp Neurol 2006, 199:499-512.
22. Litteljohn D., Mangano E.N., Hayley S. Cyclooxygenase-2 deficiency modifies the neurochemical effects, motor impairment and co-morbid anxiety provoked by paraquat administration in mice. Eur J Neurosci 2008, 28:707-716.
23. Litteljohn D., Mangano E., Shukla N., Hayley S. Interferon-gamma deficiency modifies the motor and co-morbid behavioral pathology and neurochemical changes provoked by the pesticide paraquat. Neuroscience 2009, 164:1894-1906.
24. Mayberg H.S. Frontal lobe dysfunction in secondary depression. J Neuropsychiatry Clin Neurosci 1994, 6:428-442.
25. Mayeux R. Depression in the patient with Parkinson's disease. J Clin Psychiatry 1990, 51(Suppl:20-23):24-25. [discussion].
26. Mayeux R., Williams J.B., Stern Y., Cote L. Depression and Parkinson's disease. Adv Neurol 1984, 40:241-250.
27. McDonald W.M., Richard I.H., DeLong M.R. Prevalence, etiology, and treatment of depression in Parkinson's disease. Biol Psychiatry 2003, 54:363-375.
28. Menza M., Dobkin R.D., Marin H. Treatment of depression in Parkinson's disease. Curr Psychiatry Rep 2006, 8:234-240.
29. Miller K.M., Okun M.S., Fernandez H.F., Jacobson C.E.T., Rodriguez R.L., Bowers D. Depression symptoms in movement disorders: comparing Parkinson's disease, dystonia, and essential tremor. Mov Disord 2007, 22:666-672.
30. Owen A.M. Cognitive dysfunction in Parkinson's disease: the role of frontostriatal circuitry. Neuroscientist 2004, 10:525-537.
31. Pankova N.B., Vetrile L.A., Basharova L.A., Krupina N.A., Khlebnikova N.N., Rodina V.I., et al. Immunization of rats with conjugates of dopamine and serotonin with bovine serum albumin prevents the development of experimental MPTP-induced depressive syndrome (electrophysiological parameters). Neurosci Behav Physiol 2004, 34:131-138.
32. Papp M., Willner P., Muscat R. An animal model of anhedonia: attenuation of sucrose consumption and place preference conditioning by chronic unpredictable mild stress. Psychopharmacology (Berl) 1991, 104:255-259.
33. Paxinos G., Watson C. The rat brain in stereotaxic coordinates 2005, Academic Press, San Diego. 5th edition.
34. Pierucci M., Di Matteo V., Benigno A., Crescimanno G., Esposito E., Di Giovanni G. The unilateral nigral lesion induces dramatic bilateral modification on rat brain monoamine neurochemistry. Ann N Y Acad Sci 2009, 1155:316-323.
35. Poewe W.H., Rascol O., Quinn N., Tolosa E., Oertel W.H., Martignoni E., et al. Efficacy of pramipexole and transdermal rotigotine in advanced Parkinson's disease: a double-blind, double-dummy, randomised controlled trial. Lancet Neurol 2007, 6:513-520.
36. Porsolt R.D., Anton G., Blavet N., Jalfre M. Behavioural despair in rats: a new model sensitive to antidepressant treatments. Eur J Pharmacol 1978, 47:379-391.
37. Reksidler A.B., Lima M.M.S., Zanata S.M., Machado H.B., da Cunha C., Andreatini R., et al. The COX-2 inhibitor parecoxib produces neuroprotective effects in MPTP-lesioned rats. Eur J Pharmacol 2007, 560:163-175.
38. Reksidler A.B., Lima M.M.S., Dombrowski P., Andersen M.L., Zanata S.M., Andreatini R., et al. Repeated intranigral MPTP administration: a new protocol of prolonged locomotor impairment mimicking Parkinson's disease. J Neurosci Meth 2008, 167:268-277.
39. Reksidler A.B., Lima M.M.S., Dombrowski P., Barnabé G.F., Andersen M.L., Tufik S., et al. Distinct effects of intranigral l-DOPA Infusion in the MPTP rat model of Parkinson's disease. J Neural Transm Suppl 2009, 73:259-268.
40. Reneric J.P., Bouvard M., Stinus L. In the rat forced swimming test, chronic but not subacute administration of dual 5-HT/NA antidepressant treatments may produce greater effects than selective drugs. Behav Brain Res 2002, 136:521-532.
41. Saravanan K.S., Sindhu K.M., Mohanakumar K.P. Acute intranigral infusion of rotenone in rats causes progressive biochemical lesions in the striatum similar to Parkinson's disease. Brain Res 2005, 1049:147-155.
42. Schmitz C., Hof P.R. Recommendations for straightforward and rigorous methods of counting neurons based on a computer simulation approach. J Chem Neuroanat 2000, 20:93-114.
43. Schrag A. Psychiatric aspects of Parkinson's disease-an update. J Neurol 2004, 251:795-804.
44. Segura Aguilar J., Kostrzewa R.M. Neurotoxins and neurotoxic species implicated in neurodegeneration. Neurotox Res 2004, 6:615-630.
45. Slattery D.A., Markou A., Cryan J.F. Evaluation of reward processes in an animal model of depression. Psychopharmacology (Berl) 2007, 190:555-568.
46. Tadaiesky M.T., Dombrowski P.A., Figueiredo C.P., Cargnin-Ferreira E., Da Cunha C., Takahashi R.N. Emotional, cognitive and neurochemical alterations in a premotor stage model of Parkinson's disease. Neuroscience 2008, 156:830-840.
47. Tandberg E., Larsen J.P., Aarsland D., Laake K., Cummings J.L. Risk factors for depression in Parkinson disease. Arch Neurol 1997, 54:625-630.
48. Thiffault C., Langston J.W., Di Monte D.A. Increased striatal dopamine turnover following acute administration of rotenone to mice. Brain Res 2000, 885:283-288.
49. Unger E.L., Mazzola-Pomietto P., Murphy D.L., Andrews A.M. 2'-NH(2)-MPTP [1-methyl-4-(2'-aminophenyl)-1, 2, 3, 6-tetrahydropyridine] depletes serotonin and norepinephrine in rats: a comparison with 2'-CH(3)-MPTP [1-methyl-4-(2'-methylphenyl)-1, 2, 3, 6-tetrahydropyridine]. J Pharmacol Exp Ther 2002, 303:527-533.
50. Vuckovic M.G., Wood R.I., Holschneider D.P., Abernathy A., Togasaki D.M., Smith A., et al. Memory, mood, dopamine, and serotonin in the 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine-lesioned mouse model of basal ganglia injury. Neurobiol Dis 2008, 32:319-327.
51. Wang S.H., Zhang Z.J., Guo Y.J., Zhou H., Teng G.J., Chen B.A. Anhedonia and activity deficits in rats: impact of post-stroke depression. J Psychopharmacol 2009, 23:295-304.
52. Winter C., von Rumohr A., Mundt A., Petrus D., Klein J., Lee T., et al. Lesions of dopaminergic neurons in the substantia nigra pars compacta and in the ventral tegmental area enhance depressive-like behavior in rats. Behav Brain Res 2007, 184:133-141.